Munro Partners Sells 200,770 Shares of Insulet Corporation $PODD

Munro Partners cut its stake in Insulet Corporation (NASDAQ:PODD) by 88.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,470 shares of the medical instruments supplier’s stock after selling 200,770 shares during the period. Munro Partners’ holdings in Insulet were worth $7,524,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Insulet by 1.0% in the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after acquiring an additional 87,845 shares during the last quarter. State Street Corp boosted its holdings in Insulet by 2.1% in the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after acquiring an additional 65,317 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after acquiring an additional 41,019 shares during the last quarter. Norges Bank bought a new stake in Insulet in the fourth quarter valued at approximately $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Insulet by 3.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock valued at $229,131,000 after acquiring an additional 29,690 shares during the last quarter.

Insulet Price Performance

Shares of PODD opened at $148.14 on Tuesday. Insulet Corporation has a 52-week low of $140.63 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The business’s 50 day moving average price is $168.80 and its two-hundred day moving average price is $230.66. The firm has a market cap of $10.26 billion, a PE ratio of 34.45, a price-to-earnings-growth ratio of 1.18 and a beta of 1.13.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same period in the previous year, the firm earned $1.02 earnings per share. The company’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts anticipate that Insulet Corporation will post 6.46 EPS for the current year.

Insider Transactions at Insulet

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on PODD shares. Wells Fargo & Company reduced their target price on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Sanford C. Bernstein reduced their target price on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. William Blair started coverage on Insulet in a report on Wednesday, May 20th. They issued an “outperform” rating on the stock. Citigroup reduced their target price on Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Finally, Stifel Nicolaus dropped their price target on Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $240.78.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.